Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on ITCI stock, giving a Buy rating today. Jason Gerberry ...

Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression in adults. As with other drugs, Caplyta can cause side effects, such as sleepiness ...

Intra-Cellular Therapies has established itself as a key player in the psychiatric and neurological treatment space, primarily through the success of CAPLYTA. This atypical antipsychotic drug ...

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) reached a 52-week high on Wednesday after the New York biopharma raised its outlook for its lead product, Caplyta, on the back of better-than ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, has been making significant strides in the market ...

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...